IL6ST and craniosynostosis: The therapeutic implication for patients with pathogenic IL6ST variants depends on the underlying condition ranging from intensive neonatal and supportive care in patients with Stuve-Wiedemann syndrome, antibiotic and antifungal treatment, and prophylaxis in patients with IL6ST-associated HIES, surgery in patients with craniosynostosis to immunomodulatory treatment in patients with gain-of-function variants.